Laura Joszt

Challenging Fixed Age Cut-Offs for AML Treatment, Clinical Trials

Revumenib Granted FDA Approval for R/R NPM1-Mutated AML

FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC

Weighing Osimertinib vs Amivantamab-Lazertinib in Frontline EGFR NSCLC: Danny Nguyen, MD

White House, Pfizer Reach Agreement on Drug Discounts; Trump Announces TrumpRx

Individualizing Treatment for Patients With AML Unfit for Intensive Chemo

AML Survival After 3 Years in Remission Comparable With General Population

The subcutaneous dose had comparable efficacy to intravenous dosing while enhancing patient convenience in non–small cell lung cancer, explains Nicolas Girard, MD, PhD.

Broad COVID-19 vaccination proves economically beneficial, especially for older adults, highlighting significant health and financial advantages.

Digital patient profiles and expansive real-world data are reshaping oncology clinical trials, explained Gen Li, PhD, MBA, president and founder of Phesi.